Table 6 Logistic regression analysis to identify patients harboring the T790M substitution upon rebiopsy (n = 89)
Variables | Univariate Analyses | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
OR | 95%CI | P-value | OR | 95%CI | P-value | |
Original mutation; absent vs. present | 30.5 | 8.05–115.3 | < 0.001 | 41.5 | 6.53–264.3 | < 0.001 |
Type of Biopsy; Liquid vs. Tissue | 14.6 | 5.04–42.6 | < 0.001 | NI | ||
Detection of New tumor lesion; < 4 vs 4 ≤ | 5.67 | 2.24–14.4 | < 0.001 | NI | ||
Number of Tissue biopsy | 5.72 | 2.30–14.2 | < 0.001 | NI | ||
Detection of New metastatic organ; 0 → 4 | 2.35 | 1.39–3.97 | 0.001 | NI | ||
Number of tumor lesion; < 6 vs 6 ≤ | 5.61 | 2.0–15.7 | 0.001 | NI | ||
Brain metastases; absent vs. present | 4.40 | 1.71–11.3 | 0.002 | 27.8 | 3.13–247.8 | 0.003 |
Bone metastases; absent vs. present | 3.94 | 1.55–9.98 | 0.004 | NI | ||
Number of Liquid biopsy | 0.69 | 0.52–0.90 | 0.006 | NI | ||
Enlargement of Tumor size; < 12 mm vs 12 mm ≤ | 3.47 | 1.42–8.49 | 0.007 | 24.5 | 2.65–226.7 | 0.005 |
New brain metastases; absent vs. present | 4.5 | 1.26–16.1 | 0.02 | NI | ||
Mutation site at initial diagnosis; Exon19 Deletion vs. L858R | 3.08 | 1.06–8.95 | 0.04 | 3.90 | 0.63–24.3 | 0.145 |
Minor site metastases; absent vs. present | 4.20 | 1.07–16.5 | 0.04 | 21.3 | 1.40–325.6 | 0.03 |
New hepatic metastases; absent vs. present | 3.64 | 0.85–15.7 | 0.08 | NI | ||
New minor site metastases; absent vs. present | 4.48 | 0.82–24.6 | 0.08 | NI | ||
Hepatic metastases; absent vs. present | 2.54 | 0.99–1.09 | 0.141 | NI | ||